Spyre Therapeutics (SYRE) Amortizatization of Intangibles (2015 - 2026)

Spyre Therapeutics has reported Amortizatization of Intangibles for 12 years, with the latest figure at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Amortizatization of Intangibles fell 22.07% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at -$583000.0 (down 105.02% YoY), and the FY2024 full-year result was $11.4 million, up 5083.64% from the prior year.
• Amortizatization of Intangibles for Q1 2026 stood at $2.1 million, up from -$6.0 million in the prior quarter.
• The five-year high for Amortizatization of Intangibles was $3.6 million in Q2 2024, with the low at -$6.0 million in Q4 2025.
• Historically, Amortizatization of Intangibles has averaged $880000.0 across 5 years, with a median of $809500.0 in 2022.
• Annual changes were most pronounced in 2024 — Amortizatization of Intangibles surged 22156.25% — and 2025, when it tumbled 348.24%.
• Spyre Therapeutics' Amortizatization of Intangibles stood at $105000.0 in 2022, then dropped by 7.62% to $97000.0 in 2023, then jumped by 2393.81% to $2.4 million in 2024, then plunged by 348.24% to -$6.0 million in 2025, then jumped by 134.29% to $2.1 million in 2026.
• The last three Amortizatization of Intangibles figures came in at $2.1 million (Q1 2026), -$6.0 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.